Overview

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about the cause of CP/CPPS. Likewise, no definitive therapy exists for CP/CPPS. We plan to study the use of CC-10004 in men with CP/CPPS.
Phase:
Phase 2
Details
Lead Sponsor:
Kenneth Peters, MD
Collaborator:
Celgene Corporation
Treatments:
Apremilast
Thalidomide